Translational Oncology and the rise of Immunotherapy
October 23, 2015
November 4, 2015
The Museum of Science, Boston, Massachusetts, USA.
Why not join us at this FREE Symposium. A unique opportunity to hear from some of the leading scientists in Oncology about current thinking and cutting-edge research in translating candidates successfully into the clinic. Click here to download the agenda:
Arijit Chakravarty, Director, Modeling and Simulation (DMPK), Takeda Pharmaceuticals International Co.: Deconstructing the promise of targeted therapy: genomic versus empirical approaches to personalization.
Dr Noel R. Monks, Scientist II, Oncology Research, MedImmune.: Beyond Efficacy: Improving the Clinical Relevance of PDX Models.
Dr Brian Long, Director, in vivo Pharmacology Oncology, Merck, Sharpe & Dohme.: Preclinical Strategies to Support Clinical Development of the Anti-PD-1 Antibody Keytruda.
Dr Keith Mikule, Senior Principal Scientist, R&D, Tesaro, Inc.: A mouse avatar tumor maintenance study identified a subset of SCLC patient-derived tumor xenograft models sensitive to the PARP inhibitor niraparib.
Dr Christopher Murriel, Senior Scientist, Cancer Biology, Oncomed Pharmaceuticals, Inc.: Modeling Clinical Response and Biomarker Development of Cancer Stem Cell Therapeutics Using Patient-derived Tumor Models.
Dr Henry Li, VP of Translational Oncology, Crown Bioscience Inc.: Molecular pathology of cancer patients, patient derived xenograft and cancer cell lines.
Dr Qian Shi, VP of Cancer Pharmacology, Crown Bioscience Inc.: Profiling of Syngeneic Models with Immune Checkpoint Inhibitors, FACS and RNAseq Analysis Provide Predictive Biomarkers for Cancer Immunotherapy.
Crown Bioscience's Translational Platform for Oncology and Immunotherapeutics leverages the world's largest commercial collection of PDX in Human Surrogate Trials (HuTrial™) to accelerate the successful translation of novel oncology therapies into the clinic, as well as the most comprehensive range of dedicated in vitro and in vivo services to power your oncology drug discovery projects. With a constantly growing, globally diverse collection of over 2,000 PDX, and 8,000 Tumor tissues, humanised models for immunotherapeutics, and the capacity to run 100s of models in parallel, let's talk about how we can help you accelerate the transition of your lead candidate into the clinic.
Click here to join our mailing list to be kept up to date with the latest on Crown, our models and Translational Platform. For more information about us and our services, contact us today. To reserve your place at the Symposium, simply email us today at email@example.com .